BIOVILDA M 500 (Metformin (500mg) + Vildagliptin (50mg))

Biovilda M-500 is a formulated tablet that combines two active ingredients: Vildagliptin at a dosage of 50 mg and Metformin Hydrochloride at 500 mg. This medication is primarily indicated for the treatment and management of type 2 diabetes mellitus. Vildagliptin functions as a DPP-4 (dipeptidyl peptidase-4) inhibitor, a mechanism that enhances the secretion of insulin in response to elevated blood glucose levels, while simultaneously reducing the release of glucagon—a hormone that raises blood sugar. This dual action helps to effectively lower postprandial (after meal) blood sugar levels. Metformin contributes to the therapeutic effect by enhancing the body’s sensitivity to insulin, which facilitates better glucose uptake by cells and diminishes hepatic glucose production. The synergistic action of these two components aids in achieving improved glycemic control, making it easier for patients to manage their blood sugar levels more effectively. Furthermore, by promoting overall metabolic health, Biovilda M-500 plays a crucial role in the long-term management of type 2 diabetes, which can help mitigate the risk of diabetes-related complications. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.